Cheplapharm expands in-house manufacturing capabilities in major Sanofi deal
The deal builds on a relationship between the companies that began in 2014, including previous transfers of mature medicines from Sanofi to Cheplapharm.
GERMANY— Cheplapharm has agreed to acquire a portfolio of 20 mature medicines and three manufacturing facilities from Sanofi as part of a strategic partnership between the two companies.
Under the proposed transaction, Sanofi will take a 26.4% equity stake in Cheplapharm.
The deal builds on a relationship between the companies that began in 2014, including previous transfers of mature medicines from Sanofi to Cheplapharm.
The portfolio includes Lovenox and Clexane, both brands of enoxaparin, an anticoagulant used to prevent and treat blood clots.
Cheplapharm said its operating model suits established medicines, which can require different manufacturing, regulatory and commercial approaches than newer products.
As part of the transaction, Cheplapharm will also take over three manufacturing facilities in Hungary, Singapore and France.
The sites are located in Csanyikvölgy, Jurong and Ploërmel, respectively, and employ approximately 400, 100 and 65 people.
Maintaining production and employment
The companies said they will work together to manage the transition and maintain supply to patients during the changeover.
Existing employment terms and collective agreements are expected to remain in place at the three facilities.
Sanofi General Medicines executive vice-president Thomas Grenier said the company’s efforts over several years to simplify its mature medicines portfolio have allowed it to focus more closely on innovation while continuing to support access to established treatments.
“Cheplapharm has been a trusted partner for more than a decade,” Grenier said, adding that the transaction builds on previous acquisitions from Sanofi’s mature medicines portfolio.
He said Sanofi’s planned equity investment in Cheplapharm also reflects its commitment to maintaining access to essential medicines while continuing to develop new treatments.
Transition planned for 2027
The commercial transition is expected to begin in the first quarter of 2027, with completion targeted for the third quarter.
The timetable remains subject to regulatory approvals and employee consultations.
Sanofi said the transaction is not expected to affect its financial guidance for 2026.
The companies have not disclosed further financial details about the deal.
The agreement comes as Sanofi continues to reshape its portfolio while investing in newer medicines and technologies.
In June, the company received approval from Japan’s Ministry of Health, Labour and Welfare for a subcutaneous formulation of Sarclisa (isatuximab).
The treatment is approved for use with standard therapies in patients with multiple myeloma.
Be the first to leave a comment